In lung cancer, the angiogenic switch is governed by the balance between pro-angiogenic factors, such as Vascular Endothelial Growth Factor (VEGF), and anti-angiogenic factors, including thrombospondin-1. The gene discussed is VEGFA; the disease is lung carcinoma.